Cellular Dynamics Issued U.S. Patent Covering Differentiation of iPS Cells Into Endothelial, Hematopoietic Cells
This method is used by CDI for the creation of its iCell® and MyCell® Products and enables the production of high quality cells at industrial volumes. Endothelial cells are important for the study of vascular disease research and therapy, including atherosclerosis (the build-up of plaques within blood vessels that can lead to tissue damage and even death), the body’s inflammatory responses to general injury, and the generation of new blood vessels and tissues during healing. Hematopoietic cells include a diverse set of cell types, including erythroid cells (red blood cells), lymphocytes (white blood cells), and myelocytes (bone marrow cells). Readily available, high quality sources of these cells may lead to improvements in many clinical settings including cell-based therapies, cancer treatments, organ transplantation, and treatment for autoimmune diseases.
Bob Palay, chairman and chief executive officer of CDI, said, “CDI is committed to innovation and working to create the tissue cells critical to research impacting human health. This patent covers a reliable, scalable method for creating a consistent supply of blood and blood vessel cells in high quality, quantity and purity from iPS cells and continues CDI’s intellectual property strategy of assembling a broad portfolio of patents and licenses for all of our products.”
This is the fifth patent issued to CDI this year, adding to an intellectual property portfolio of over 700 patents.
Follow us on Twitter @CellDynamics or www.twitter.com/celldynamics
To the extent that statements contained in this press release are not descriptions of historical facts regarding
CONTACT: MEDIA CONTACTS:
Joleen RauSenior Director, Marketing & Communications
Cellular Dynamics International, Inc.
Robert E. Flamm, Ph.D.
Russo Partners LLC
Gitanjali Jain Ogawa The Trout Group, LLC
News Provided by Acquire Media